Lead Product(s) : APTO-253
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose Provides Update on APTO-253 Program
Details : APTO-253 remains an interesting product that has demonstrated MYC repression, which creates optionality across the wider oncology spectrum. Clinical development of the MYC repressor APTO-253 will be discontinued.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : APTO-253
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
Details : Early clinical data, along with certain preclinical data, for CG-806, an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor, and early clinical data for APTO-253, a small molecule MYC inhibitor, will be presented at the 62nd ASH Annual ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2020
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Details : APTO-253 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2014
Reset All
